Stock comparison
Harmony Biosciences Holdings
Krystal Biotech
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HRMY
Harmony Biosciences Holdings
Market cap
$1.75B
Sector
Healthcare
KRYS
Krystal Biotech
Market cap
$8.83B
Sector
Healthcare
Overall winner
Krystal Biotech KRYS
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HRMY | KRYS | Winner |
|---|---|---|---|
| Warren Buffett | 67B | 51C | HRMY |
| Benjamin Graham | 60C | 74D | KRYS |
| Philip Fisher | 75B | 74C | HRMY |
| Peter Lynch | 62C | 58C | HRMY |
| Joel Greenblatt | 28F | 59C | KRYS |
| Charlie Munger | 62C | 64D | KRYS |
| Terry Smith | 67B | 64D | HRMY |
Side-by-side metrics
| Metric | HRMY | KRYS |
|---|---|---|
| Market cap | $1.75B | $8.83B |
| P/E (TTM) | 11.8x | 39.9x |
| EV/EBIT | 6.4x | 52.9x |
| ROIC (TTM) | 12.5% | 13.85% |
| Gross margin | 76.55% | 92.79% |
| Net margin | 16.2% | 53.92% |
| Revenue CAGR 5y | 29.85% | - |
| EPS CAGR 5y | 46.45% | - |
| Debt / Equity | 0.2x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HRMY leads on
- EV/EBIT6.4xvs 52.9x+88%
- P/E (TTM)11.8xvs 39.9x+70%
KRYS leads on
- Debt / Equity0.0xvs 0.2x+99%
- Market cap$8.83Bvs $1.75B+80%
- Net margin53.92%vs 16.2%+70%
- Gross margin92.79%vs 76.55%+18%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.